Team IAA

Completed Projects · Platform Technologies

Team IAA

Rapid Identification of Auto-Antigens in Autoimmune Diseases

The team is seeking new platform technologies or concepts which lead to identification of antigens recognized by T-cells involved in autoimmune responses. The objective of the group is to deconvolute the autoimmune T-cell receptor (TCR) repertoire functionally with respect to unknown cognate peptide: HLA complexes. We will use high-throughput screening approaches coupling sequence to specificity in order to identify critical points of attack in the treatment of autoimmune diseases.


  1. Cetin M, Pinamonti V, Schmid T, Boschert T, Mellado Fuentes A, Kromer K, Lerner T, Zhang J, Herzig Y, Ehlert C, Hernandez-Hernandez M, Samaras G, Torres CM, Fisch L, Dragan V, Kouwenhoven A, Van Schoubroeck B, Wils H, Van Hove C, Platten M, Green EW, Stevenaert F, Felix NJ, Lindner JM (2024):
    T-FINDER: A highly sensitive, pan-HLA platform for functional T cell receptor and ligand discovery.
    Science Advances
  2. Boschert T, Kromer K, Lerner T, Lindner K, Haltenhof G, Tan CL, Jähne K, Poschke I, Bunse L, Eisele P, Grassl N, Mildenberger I, Sahm K, Platten M, Lindner JM, Green EW (2024):
    H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient.
    Science Advances
  3. Tan, CL, Lindner, K, Boschert, T, Meng, Z, Rodriguez Ehrenfried, A, De Roia, A, Haltenhof, G, Faenza, A, Imperatore, F, Bunse, L, Lindner, JM, Harbottle, RP, Ratliff, M, Offringa, R, Poschke, I, Platten, M, Green, EW (2024): Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy.
    Nat Biotechnol
The research of this team was kindly sponsored by Johnson & Johnson Innovative Medicine.